More Sen­a­tors ac­cuse Marathon CEO Aronin of ex­ploit­ing Duchenne MD pa­tients as well as FDA’s or­phan in­cen­tives

A group of US Sen­a­tors is tight­en­ing the screws on Marathon Phar­ma­ceu­ti­cals in the wake of the lat­est drug pric­ing scan­dal.

Just weeks af­ter Marathon CEO Jeff Aronin man­aged to out­rage a host of Duchenne mus­cu­lar dy­s­tro­phy fam­i­lies and Ver­mont Sen­a­tor Bernie Sanders with his de­ci­sion to price a cheap, gener­ic steroid at $89,000 a year af­ter fi­nagling an FDA ap­proval and some lu­cra­tive in­cen­tives specif­i­cal­ly tai­lored to the dis­ease, a group of US Sen­a­tors has come to­geth­er to step up de­mands for an­swers from the com­pa­ny about what it ac­tu­al­ly spent to prep this ther­a­py for an ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER